PSP Research LLC Acquires New Position in Halozyme Therapeutics, Inc. $HALO

PSP Research LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, Holdings Channel.com reports. The firm acquired 8,026 shares of the biopharmaceutical company’s stock, valued at approximately $540,000. Halozyme Therapeutics accounts for 0.5% of PSP Research LLC’s investment portfolio, making the stock its 23rd biggest holding.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Tredje AP fonden acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $2,019,000. Handelsbanken Fonder AB lifted its stake in shares of Halozyme Therapeutics by 52.4% in the fourth quarter. Handelsbanken Fonder AB now owns 591,869 shares of the biopharmaceutical company’s stock valued at $39,833,000 after purchasing an additional 203,500 shares during the period. Profund Advisors LLC lifted its stake in shares of Halozyme Therapeutics by 46.6% in the fourth quarter. Profund Advisors LLC now owns 36,100 shares of the biopharmaceutical company’s stock valued at $2,430,000 after purchasing an additional 11,469 shares during the period. ProShare Advisors LLC lifted its stake in shares of Halozyme Therapeutics by 8.4% in the fourth quarter. ProShare Advisors LLC now owns 9,909 shares of the biopharmaceutical company’s stock valued at $667,000 after purchasing an additional 767 shares during the period. Finally, Envestnet Portfolio Solutions Inc. raised its position in Halozyme Therapeutics by 3.6% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 14,028 shares of the biopharmaceutical company’s stock worth $944,000 after acquiring an additional 485 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $68.73 on Wednesday. Halozyme Therapeutics, Inc. has a 12 month low of $51.06 and a 12 month high of $82.22. The company has a 50-day simple moving average of $65.67 and a 200-day simple moving average of $68.70. The company has a market cap of $8.15 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same period in the previous year, the firm earned $1.11 earnings per share. Halozyme Therapeutics’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $69.19, for a total value of $691,900.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $53,122,698.20. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total transaction of $599,087.48. Following the completion of the sale, the chief operating officer owned 7,055 shares of the company’s stock, valued at approximately $477,200.20. The trade was a 55.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 120,482 shares of company stock worth $8,200,842. 2.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of research reports. Benchmark lifted their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Finally, HC Wainwright lifted their target price on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $80.67.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.